Abbott, a leading HIV/AIDS research company announced on 28th. April that The US Food and Drug Administration (FDA) has approved once-daily dosing of lopinavir/ritonavir tablets and oral solution (Kaletra; Abbott Laboratories) for adult patients with HIV-1 who have previously taken antiretroviral therapy and have 2 or fewer key mutations in the virus’ protease gene.

A little bit history here from AIDSInfo: Lopinavir/ritonavir in capsule and oral solution form was approved by the FDA on September 15, 2000, for use with other antiretrovirals in the treatment of HIV infection in adults and children 6 months of age or older. Lopinavir/ritonavir in tablet form was approved by the FDA on October 28, 2005. In March 2006, the capsule form of the medicine was phased out in the U.S. in favor of the new tablet.

once-daily dosing of lopinavir/ritonavir tablets and oral solution means lopinavir/ritonavir can be used noce or twice a day (as recommended before) combining with other therapies. This will be an easiler way of treatment and may reduce further poor adherence among HIV-diagnosed patients, which is critical for immunosupression and virological suppression.